FDA Approves Drug to Reduce Accidental Food Allergies FDA Approves Drug to Reduce Accidental Food Allergies
The new indication makes Xolair (omalizumab) the first drug approved to mitigate allergic reactions to more than one food.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 16, 2024 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology Source Type: news
First Drug OK'd for Reducing Allergic Reactions From Multiple Foods
(MedPage Today) -- The FDA approved omalizumab (Xolair) injection, the first medication to help reduce allergic reactions to multiple foods after accidental exposure, the agency announced Friday.
A monoclonal antibody, omalizumab is indicated... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - February 16, 2024 Category: Allergy & Immunology Source Type: news
FDA Expands Use of Asthma Med Xolair to Treat Food Allergies
FRIDAY, Feb. 16, 2024 -- People threatened by accidental exposure to foods they ' re allergic to may have a new weapon of defense: On Friday, the U.S. Food and Drug Administration expanded the use of the asthma drug Xolair to help prevent... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 16, 2024 Category: General Medicine Source Type: news
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies
South San Francisco, CA -- February 16, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Xolair® (omalizumab) for the reduction of allergic... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 16, 2024 Category: Drugs & Pharmacology Source Type: news
FDA expands use of asthma drug Xolair to treat severe food allergies
A medication used to treat asthma can now be used to help people with food allergies avoid severe reactions (Source: ABC News: Health)
Source: ABC News: Health - February 16, 2024 Category: Consumer Health News Tags: Health Source Type: news
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placeboMore than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2 Detailed OUtMATCH results will be featured in a late-breaking symposiumat the 2024 AAAAI Annual MeetingBasel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food ...
Source: Roche Investor Update - February 16, 2024 Category: Pharmaceuticals Source Type: news
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placeboMore than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2 Detailed OUtMATCH results will be featured in a late-breaking symposiumat the 2024 AAAAI Annual MeetingBasel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food ...
Source: Roche Media News - February 16, 2024 Category: Pharmaceuticals Source Type: news
Variety Promotes Lindsey Elfenbein to VP of Global Summits and Strategic Partnerships
Variety has promoted Lindsey Elfenbein to VP of global summits and strategic partnerships. In her elevated role, Elfenbein will continue to oversee the brand’s global thought-leadership vertical and expand Variety’s portfolio of B2B and consumer clients across tech, financial, consultancy and…#variety #lindseyelfenbein #elfenbein #michellefinesmith #svp #adobe #allergan #citynationalbank #deloitte #pwc (Source: Reuters: Health)
Source: Reuters: Health - February 16, 2024 Category: Consumer Health News Source Type: news
Improve Your Dx of This Oft-Missed Genital Disorder Improve Your Dx of This Oft-Missed Genital Disorder
The nonspecific symptoms of lichen sclerosus often lead to a missed or delayed diagnosis, exacerbating the challenges that patients with the condition face.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 16, 2024 Category: Allergy & Immunology Tags: Family Medicine/Primary Care Source Type: news
Tapinarof Under FDA Review for Treating Atopic Dermatitis Tapinarof Under FDA Review for Treating Atopic Dermatitis
Approved in 2022 for psoriasis, the manufacturer has submitted an application for approval of tapinarof cream for treating atopic dermatitis in adults and children 2 years of age and older.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 16, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
Exclusive-Wegovy Fuels Sharp Rise in Use Of Weight-loss Drugs for US Youth Exclusive-Wegovy Fuels Sharp Rise in Use Of Weight-loss Drugs for US Youth
A small but rapidly growing number of U.S. adolescents began treatment with Novo Nordisk ' s<NOVOb.CO> weight-loss drug Wegovy last year, a powerful new tool to address...Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 15, 2024 Category: Allergy & Immunology Tags: Diabetes & Endocrinology Source Type: news
Eosinophilic Esophagitis: 5 Things to Know Eosinophilic Esophagitis: 5 Things to Know
Although delayed diagnosis of EoE presents considerable risk to those with this chronic inflammatory disease, novel treatments are providing hope that a new era is on the horizon.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 15, 2024 Category: Allergy & Immunology Tags: Gastroenterology Source Type: news
The PALACE Trial: Rethinking New Penicillin Allergy Coding The PALACE Trial: Rethinking New Penicillin Allergy Coding
Dr Kevin Fernando reviews how to recognize and rectify erroneously coded penicillin allergies using data from the PALACE trial.Medscape Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 14, 2024 Category: Consumer Health News Tags: Internal Medicine Commentary Source Type: news
It's Risky to Mix Paxlovid With Immunosuppressants It's Risky to Mix Paxlovid With Immunosuppressants
The EMA has warned that Paxlovid should only be administered alongside tacrolimus, ciclosporin, everolimus, or sirolimus if their blood levels can be closely monitored.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 14, 2024 Category: Allergy & Immunology Tags: Pharmacist Source Type: news
Lab Testing in Patients on Immunomodulators Falls Short Lab Testing in Patients on Immunomodulators Falls Short
Review found that fewer than 60% of patients with chronic inflammatory skin diseases underwent recommended testing before starting systemic immunomodulator treatment.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 14, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
